Singapore, March 24 -- German multinational leader Qiagen has announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.

This collaboration follows the US Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.

Together, Qiagen and IPPA are committed to promoting the use of IGRA testing, such as Qiagen's QuantiFERON-TB Plus, to ensure a safe immigration process and ...